www.diseases-diagnosis.com Homepage Diseases Symptoms Diseases Diagnosis Diseases Treatment Diseases Living Care Diseases Prevention Diseases Research
www
Search
Wednesday, September 13th, 2017
Table of Contents

1 Introduction
5 PMID
 [F] Diseases Research  / PubMed Research Articles  /
Balanced Coagonist of GLP-1 and Glucagon Receptors Corrects Dyslipidemia by Improving FGF21 Sensitivity in Hamster Model.

PubMed

 

Resource

Drug research 2017 Sep 12; ()

Authors

Patel V1; Joharapurkar A2; Kshirsagar S3; Patel HM4; Pandey D5; Patel D6; Sutariya B7; Patel M8; Bahekar R9; Jain MR10;

Author Information
  • 1Department of Pharmacology & Toxicology, Zydus Research Centre, Cadila Healthcare Limited, Moraiya, Ahmedabad, India.
  • 2Department of Pharmacology & Toxicology, Zydus Research Centre, Cadila Healthcare Limited, Moraiya, Ahmedabad, India.
  • 3Department of Pharmacology & Toxicology, Zydus Research Centre, Cadila Healthcare Limited, Moraiya, Ahmedabad, India.
  • 4Department of Pharmacology & Toxicology, Zydus Research Centre, Cadila Healthcare Limited, Moraiya, Ahmedabad, India.
  • 5Department of Pharmacology & Toxicology, Zydus Research Centre, Cadila Healthcare Limited, Moraiya, Ahmedabad, India.
  • 6Department of Medicinal Chemistry, Zydus Research Centre, Cadila Healthcare Limited, Moraiya, Ahmedabad, India.
  • 7Department of Pharmacology & Toxicology, Zydus Research Centre, Cadila Healthcare Limited, Moraiya, Ahmedabad, India.
  • 8Department of Pharmacology & Toxicology, Zydus Research Centre, Cadila Healthcare Limited, Moraiya, Ahmedabad, India.
  • 9Department of Medicinal Chemistry, Zydus Research Centre, Cadila Healthcare Limited, Moraiya, Ahmedabad, India.
  • 10Department of Pharmacology & Toxicology, Zydus Research Centre, Cadila Healthcare Limited, Moraiya, Ahmedabad, India.

Abstract

Hyperlipidemia is often associated with obesity and diabetes, and can lead to serious complications like atherosclerosis and fatty liver disease. Coagonist of GLP-1 and glucagon receptors is a therapy under clinical investigation for treatment of obesity and diabetes. In this study, we have characterized the mechanism of hypolipidemic effect of a balanced coagonist using high cholesterol-fed hamsters. Tyloxapol-induced hypertriglyceridemia, lipolysis in adipose tissue, and bile homeostasis were assessed after repeated dose treatment of the coagonist of GLP-1 and glucagon receptors (Aib2 C24 chimera 2, SC). Antagonists of GLP-1, glucagon, and FGF21 receptors were coadministered, and FGF21 sensitivity was determined in liver and adipose tissue. Repeated dose treatment of coagonist reduced cholesterol and increased FGF21 in blood and liver. Coagonist treatment reduced hepatic triglyceride secretion, increased lipolysis and reduced body weight. Antagonism of GLP-1 and glucagon receptors partially blocked the effect of the coagonist on lipid metabolism in circulation and liver, while FGF21 receptor antagonist completely abolished it. Glucagon and GLP-1 receptors antagonists blocked the action of coagonist on cholesterol excretion and bile flow in liver, but FGF21 antagonist was not effective. Treatment with the coagonist increased expression of FGF21, FGF21R and cofactor ßKlotho in liver and adipose. In conclusion, coagonist of GLP-1 and glucagon receptors improved lipid metabolism in liver of dyslipidemic hamsters. This effect is partially mediated by GLP-1 and glucagon receptors, and the improved FGF21 sensitivity could be the mechanism of hypolipidemic action of the coagonist of GLP-1/glucagon receptors.

© Georg Thieme Verlag KG Stuttgart · New York.

PMID

28898910

Others

Publication Type: Journal Article


This article is licensed under the the National Library of Medicine License. It uses material from the PubMed National Library of Medicine Data.


Last Modified:   2016-03-27


Search
All informatin on the site is © www.diseases-diagnosis.com 2002-2016. Last revised: March 27, 2016
Are you interested in our site or/and want to use our information? please read how to contact us and our copyrights.
To let us provide you with high quality information, you can help us by making a more or less donation: